Eculizumab for the treatment of dense-deposit disease
M Vivarelli, A Pasini, F Emma - New England Journal of Medicine, 2012 - Mass Medical Soc
M Vivarelli, A Pasini, F Emma
New England Journal of Medicine, 2012•Mass Medical SocEculizumab for the Treatment of Dense-Deposit Disease | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career
with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career
with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
Dysregulation of the alternative complement pathway plays a pathogenic role in dense-deposit disease (also known as membranoproliferative glomerulonephritis type II). This letter reports the use of eculizumab in a patient with this disease.
The New England Journal Of Medicine